Crizotinib, a multitargeted tyrosine kinase inhibitor (TKI) targeting MET/ALK/ROS1, has demonstrated notable efficacy in treating NSCLC with ROS1 rearrangements. This evidence concerns the gene ALK and non-small cell lung carcinoma.